Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 2, 2012, Pages 248-255

  Liu, Wei Jing ^a,c   Xie, Shu Hua ^a   Liu, Yu Ning ^b   Kim, Won ^c   Jin, Heung Yong ^c   Park, Sung Kwang ^c   Shao, Yi Ming ^a   Park, Tae Sun ^c  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; CASPASE 3; CREATININE; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; UREA; VILDAGLIPTIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DNA DAMAGE; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; ELECTRON MICROSCOPY; ENZYME INHIBITION; FOOD INTAKE; GENE EXPRESSION; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; KIDNEY CELL; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; REPEATED DRUG DOSE; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL; URINARY ALBUMIN CREATININE RATIO; URINARY EXCRETION;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CASPASE 3; CYCLIC AMP; DEOXYGUANOSINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EATING; GENE EXPRESSION; GLOMERULAR BASEMENT MEMBRANE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; KIDNEY; MALE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84862944057     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.186866     Document Type: Article

References (38)

1. Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, et al. (2008) Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93:459-464. (Pubitemid 351240816)
2. Campbell RK and White JR Jr (2008) More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ 34:518-534.
3. Deacon CF, Hughes TE, and Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769. (Pubitemid 28201806)
4. Doyle ME and Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546-593. (Pubitemid 46365961)
5. Freeman JS (2007) The pathophysiologic role of incretins. J Am Osteopath Assoc 107 (Suppl):S6-S9.
6. Girach A and Vignati L (2006) Diabetic microvascular complications-can the presence of one predict the development of another? J Diabetes Complications 20:228-237. (Pubitemid 43949349)
7. Golubović E, Stefanović V, and Zivić S (1996) [Diagnosis of renal tubular dysfunction in insulin-dependent diabetes mellitus]. Srp Arh Celok Lek 124 (Suppl 1):43-44.
8. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, et al. (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055-3061. (Pubitemid 38766408)
9. Han DC, Hoffman BB, Hong SW, Guo J, and Ziyadeh FN (2000) Therapy with antisense TGF-β1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 278:F628-F634. (Pubitemid 30215241)
10. Harper JF and Brooker G (1975) Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1:207-218.
11. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, et al. (2009) Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380:44-49.
12. Hoffman BB, Sharma K, and Ziyadeh FN (1998) Potential role of TGF-β in diabetic nephropathy. Miner Electrolyte Metab 24:190-196. (Pubitemid 28098191)
13. Hojbjerg P, Vilsboll T, Knop FK, Bache M, Madsbad S, and Krarup T (2007) Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type 2 diabetes. Diabetes 56 (Suppl 1):A373.
14. Holst JJ, Vilsbøll T, and Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127-136.
15. Jepsen FL and Mortensen PB (1979) Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function. A quantitative study. Virchows Arch A Pathol Anat Histol 383:265-270. (Pubitemid 9234356)
16. Jin HY, Liu WJ, Park JH, Baek HS, and Park TS (2009) Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 40:536-544.
17. Kim JY, Lim DM, Moon CI, Jo KJ, Lee SK, Baik HW, Lee KH, Lee KW, Park KY, and Kim BJ (2010) Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity. J Korean Med Sci 25:1626-1632.
18. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, et al. (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965-978.
19. Kuhad A and Chopra K (2009) Attenuation of diabetic nephropathy by tocotrienol: involvement of NFκB signaling pathway. Life Sci 84:296-301.
20. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478. (Pubitemid 36043598)
21. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 106:1285-1290.
22. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, and Park TS (2011) Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 164:1410-1420.
23. Mitic B, Lazarevic G, Vlahovic P, Rajic M, and Stefanovic V (2008) Diagnostic value of the aminopeptidase N,N-acetyl-β-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail 30:896-903.
24. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, et al. (2007) Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18:1227-1238. (Pubitemid 46536909)
25. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, and White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic β cell growth and function. J Biol Chem 281:1159-1168.
26. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, and Greig NH (2002) A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958-966. (Pubitemid 34165002)
27. Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, and Laping NJ (2008) Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int 73:705-715. (Pubitemid 351323246)
28. Schlatter P, Beglinger C, Drewe J, and Gutmann H (2007) Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141:120-128. (Pubitemid 46482693)
29. Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, and Kaku K (2011) The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic β cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 54:1098-1108.
30. Teles F, Machado FG, Ventura BH, Malheiros DM, Fujihara CK, Silva LF, and Zatz R (2009) Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 75:72-79.
31. Tsakas S and Goumenos DS (2006) Accurate measurement and clinical significance of urinary transforming growth factor-β1. Am J Nephrol 26:186-193. (Pubitemid 43882404)
32. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, and Camilleri M (2007) Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56:1475-1480. (Pubitemid 46715627)
33. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC, and Bonner-Weir S (2007) Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56:1551-1558. (Pubitemid 46842610)
34. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, and Border WA (1993) Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90:1814-1818. (Pubitemid 23069947)
35. Yang J, Campitelli J, Hu G, Lin Y, Luo J, and Xue C (2007) Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 81:272-279. (Pubitemid 47030570)
36. Yu Z and Jin T (2010) New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal 22:1-8.
37. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, and Drucker DJ (2006) GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4:391-406. (Pubitemid 44752565)
38. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, and Ye W (2009) Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 247:699-706.